Methyl CpG binding protein 2 promotes colorectal cancer metastasis by regulating N 6 ‐methyladenosine methylation through methyltransferase‐like 14
RNA N 6 ‐methyladenosine (m 6 A) is an emerging regulatory mechanism for tumor progression in several types of cancer. However, the underlying regulation mechanisms of m 6 A methylation in colorectal cancer (CRC) remain unknown. Although the oncogenic function of methyl CpG binding protein 2 (MeCP2)...
Gespeichert in:
Veröffentlicht in: | Cancer science 2021-08, Vol.112 (8), p.3243-3254 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | RNA N
6
‐methyladenosine (m
6
A) is an emerging regulatory mechanism for tumor progression in several types of cancer. However, the underlying regulation mechanisms of m
6
A methylation in colorectal cancer (CRC) remain unknown. Although the oncogenic function of methyl CpG binding protein 2 (MeCP2) has been reported, it is still unclear whether MeCP2 could alter RNA m
6
A methylation state. Here, we systematically identified MeCP2 as a prometastasis gene to regulate m
6
A methylation in CRC. Interestingly, MeCP2 could bind to methyltransferase‐like 14 (METTL14) to coregulate tumor suppressor Kruppel‐like factor 4 (KLF4) expression through changing m
6
A methylation modification. Furthermore, insulin‐like growth factor 2 mRNA‐binding protein 2 recognized the unique modified m
6
A methylation sites to enhance KLF4 mRNA stability. Taken together, these findings highlight the novel function of MeCP2 for regulating m
6
A methylation and reveal the underlying molecular mechanism for the interaction between MeCP2 and METTL14, which offers a better understanding of CRC progression and metastasis. |
---|---|
ISSN: | 1347-9032 1349-7006 |
DOI: | 10.1111/cas.15011 |